TherapeuticsMD Inc. (TXMD)
TherapeuticsMD Statistics
Share Statistics
TherapeuticsMD has 11.57M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 11.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 30.6% |
| Shares Floating | 11.34M |
| Failed to Deliver (FTD) Shares | 1.44K |
| FTD / Avg. Volume | 0.49% |
Short Selling Information
The latest short interest is 146.48K, so 1.27% of the outstanding shares have been sold short.
| Short Interest | 146.48K |
| Short % of Shares Out | 1.27% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 4.42 |
Valuation Ratios
The PE ratio is -4.55 and the forward PE ratio is 7.38. TherapeuticsMD's PEG ratio is 0.07.
| PE Ratio | -4.55 |
| Forward PE | 7.38 |
| PS Ratio | 5.63 |
| Forward PS | 1.5 |
| PB Ratio | 0.36 |
| P/FCF Ratio | 8.48 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TherapeuticsMD.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.2.
| Current Ratio | 2.37 |
| Quick Ratio | 2.37 |
| Debt / Equity | 0.2 |
| Debt / EBITDA | -1.86 |
| Debt / FCF | 4.74 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.76M |
| Profits Per Employee | $-2.18M |
| Employee Count | 1 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -162K |
| Effective Tax Rate | 6.91% |
Stock Price Statistics
The stock price has increased by -33.86% in the last 52 weeks. The beta is 0.95, so TherapeuticsMD's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -33.86% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.34 |
| Relative Strength Index (RSI) | 69.52 |
| Average Volume (20 Days) | 294.24K |
Income Statement
In the last 12 months, TherapeuticsMD had revenue of 1.76M and earned -2.18M in profits. Earnings per share was -0.19.
| Revenue | 1.76M |
| Gross Profit | 1.76M |
| Operating Income | -4.76M |
| Net Income | -2.18M |
| EBITDA | -2.98M |
| EBIT | -3.49M |
| Earnings Per Share (EPS) | -0.19 |
Balance Sheet
The company has 5.06M in cash and 5.54M in debt, giving a net cash position of -483K.
| Cash & Cash Equivalents | 5.06M |
| Total Debt | 5.54M |
| Net Cash | -483K |
| Retained Earnings | -951.82M |
| Total Assets | 38.82M |
| Working Capital | 7.09M |
Cash Flow
In the last 12 months, operating cash flow was 1.17M and capital expenditures 0, giving a free cash flow of 1.17M.
| Operating Cash Flow | 1.17M |
| Capital Expenditures | 0 |
| Free Cash Flow | 1.17M |
| FCF Per Share | 0.1 |
Margins
Gross margin is 100%, with operating and profit margins of -270.3% and -123.85%.
| Gross Margin | 100% |
| Operating Margin | -270.3% |
| Pretax Margin | -133.05% |
| Profit Margin | -123.85% |
| EBITDA Margin | -169.39% |
| EBIT Margin | -270.3% |
| FCF Margin | 66.44% |
Dividends & Yields
TXMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TXMD.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on May 9, 2022. It was a backward split with a ratio of 1:50.
| Last Split Date | May 9, 2022 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -33.62 |
| Piotroski F-Score | 7 |